These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 19426230)

  • 1. The clinical utility of inhibiting CD28-mediated costimulation.
    Linsley PS; Nadler SG
    Immunol Rev; 2009 May; 229(1):307-21. PubMed ID: 19426230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis.
    Kim KS; Denton MD; Chandraker A; Knoflach A; Milord R; Waaga AM; Turka LA; Russell ME; Peach R; Sayegh MH
    Am J Pathol; 2001 Mar; 158(3):977-86. PubMed ID: 11238045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costimulation and its role in organ transplantation.
    Bluestone JA
    Clin Transplant; 1996 Feb; 10(1 Pt 2):104-9. PubMed ID: 8680045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig.
    Knoerzer DB; Karr RW; Schwartz BD; Mengle-Gaw LJ
    J Clin Invest; 1995 Aug; 96(2):987-93. PubMed ID: 7543497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costimulation blockade in autoimmunity and transplantation.
    Vincenti F
    J Allergy Clin Immunol; 2008 Feb; 121(2):299-306; quiz 307-8. PubMed ID: 18269922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges and opportunities in targeting the costimulation pathway in solid organ transplantation.
    Wojciechowski D; Vincenti F
    Semin Immunol; 2011 Jun; 23(3):157-64. PubMed ID: 21856169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.
    Ruderman EM; Pope RM
    Arthritis Res Ther; 2005; 7 Suppl 2(Suppl 2):S21-5. PubMed ID: 15833145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation.
    Vincenti F; Luggen M
    Annu Rev Med; 2007; 58():347-58. PubMed ID: 17020493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High concentrations of antigenic ligand activate and do not tolerize naive CD4 T cells in the absence of CD28/B7 costimulation.
    Teh HS; Teh SJ
    Cell Immunol; 1997 Jul; 179(1):74-83. PubMed ID: 9259774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cells of staphylococcal enterotoxin B-tolerized autoimmune MRL-lpr/lpr mice require co-stimulation through the B7-CD28/CTLA-4 pathway for activation and can be reanergized in vivo by stimulation of the T cell receptor in the absence of this co-stimulatory signal.
    Zhou T; Weaver C; Linsley PS; Mountz JD
    Eur J Immunol; 1994 May; 24(5):1019-25. PubMed ID: 7514125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTLA4-Ig: a novel immunosuppressive agent.
    Najafian N; Sayegh MH
    Expert Opin Investig Drugs; 2000 Sep; 9(9):2147-57. PubMed ID: 11060799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A more selective costimulatory blockade of the CD28-B7 pathway.
    Poirier N; Blancho G; Vanhove B
    Transpl Int; 2011 Jan; 24(1):2-11. PubMed ID: 20964725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting T cell costimulation in autoimmune disease.
    Stuart RW; Racke MK
    Expert Opin Ther Targets; 2002 Jun; 6(3):275-89. PubMed ID: 12223069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4.
    Kearney ER; Walunas TL; Karr RW; Morton PA; Loh DY; Bluestone JA; Jenkins MK
    J Immunol; 1995 Aug; 155(3):1032-6. PubMed ID: 7543510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTLA-4Ig: uses and future directions.
    Ben-Shoshan M
    Recent Pat Inflamm Allergy Drug Discov; 2009 Jun; 3(2):132-42. PubMed ID: 19519590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An inhibitor of CD28-CD80 interactions impairs CD28-mediated costimulation of human CD4 T cells.
    Fine JS; Macosko HD; Justice L; Chou CC; Jenh CH; Narula SK; Zavodny PJ
    Cell Immunol; 1999 Jan; 191(1):49-59. PubMed ID: 9918686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effect of CTLA4Ig on murine graft-versus-host disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD.
    Via CS; Rus V; Nguyen P; Linsley P; Gause WC
    J Immunol; 1996 Nov; 157(9):4258-67. PubMed ID: 8892665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of a hypoglycosylated form of CD86 (B7-2) on human T cells with altered binding properties to CD28 and CTLA-4.
    Höllsberg P; Scholz C; Anderson DE; Greenfield EA; Kuchroo VK; Freeman GJ; Hafler DA
    J Immunol; 1997 Nov; 159(10):4799-805. PubMed ID: 9366404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opposing roles of CD28:B7 and CTLA-4:B7 pathways in regulating in vivo alloresponses in murine recipients of MHC disparate T cells.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Sharpe AH; Vallera DA
    J Immunol; 1999 Jun; 162(11):6368-77. PubMed ID: 10352249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CTLA-4: a key regulatory point in the control of autoimmune disease.
    Scalapino KJ; Daikh DI
    Immunol Rev; 2008 Jun; 223():143-55. PubMed ID: 18613834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.